Ability of AcSDKP to Inhibit the Proliferation of Primitive Normal Progenitors in the Adherent Layer of Activated LTC Is Not Affected by the Addition of Anti–MIP-1α Antibodies
| Treatment . | % Kill After3H-Thymidine . | |
|---|---|---|
| Primitive BFU-E . | Primitive CFU-GM . | |
| None | 44 ± 10 | 52 ± 7 |
| AcSDKP | 10 ± 1 | 4 ± 1 |
| AcSDKP + anti–MIP-1α | 2 ± 4 | 0 ± 5 |
| AcSDKP + MIP-1β | 26 ± 7 | 33 ± 10 |
| Treatment . | % Kill After3H-Thymidine . | |
|---|---|---|
| Primitive BFU-E . | Primitive CFU-GM . | |
| None | 44 ± 10 | 52 ± 7 |
| AcSDKP | 10 ± 1 | 4 ± 1 |
| AcSDKP + anti–MIP-1α | 2 ± 4 | 0 ± 5 |
| AcSDKP + MIP-1β | 26 ± 7 | 33 ± 10 |
AcSDKP at 300 ng/mL, MIP-1α at 100 ng/mL, and anti–MIP-1α at 100 μg/mL. Results shown are the mean ±SEM of data obtained in four independent experiments. The effect of AcSDKP + anti–MIP-1α is not significantly different from the effect of AcSDKP alone (P > .05).